SCT such as BMT or cord blood transplantation (CBT) is an effective therapy for hematological malignancies. Nevertheless, there are still serious problems associated with SCT, such as secondary malignancy and relapse. Both chemotherapy and radiation for conditioning regimen before SCT are thought to be causes of genomic instability. Occasionally, they produce different types of chromosomal aberrations, which may lead to the development of secondary malignancies. Transient (clonal or nonclonal) chromosomal abnormalities after SCT have been reported by some studies, mainly observed after BMT. 1 Kim et al. described a first case with this rare event after CBT. Here, we report three cases of children with ALL who showed transient chromosomal rearrangements after unrelated CBT and discuss the possible causes and consequences of this phenomenon. In 2008, three pediatric patients with ALL underwent unrelated CBT at our center. The clinical data of these patients and the case described by Kim et al.
1 are shown in Table 1 . All our patients are boys and underwent transplantation in second clinical remission. The conditioning regimen included fractionated TBI (12 Gy TBI by 6 days), cytarabine and ATG. After CBT, the cytogenetic analysis of BM cells showed the transient chromosomal rearrangements at different times of follow-up (Table 2) . These rearrangements were transient (clonal and nonclonal) and involved different chromosome regions. In our patients, the transient chromosomal rearrangements were associated with delayed hematological recovery (case 2), primary rejection (case 3) and, mainly, autologous reconstitution without disease evidence or secondary malignancy (myelodysplastic syndrome). Nowadays, the molecular analysis by variable number tandem repeat showed that one patient has mixed chimerism (case 1) in BM sample and the other two have autologous recovery (cases 2 and 3). At the time of reporting these patients were hematologically normal (remission).
Transient (clonal or non-clonal) chromosomal abnormalities have been described in some patients after SCT. Only one of them was a patient who received CBT 1 ( Table 1) . As described by Kim et al.,
1 one of our cases was a young boy with precursor B-cell ALL. The other two patients had an unclassified ALL. However, at the time of CBT all were in second clinical remission. After CBT our patients showed transient chromosomal rearrangements in different periods of cytogenetic follow-up. Some hypotheses could explain this phenomenon. First, the disease's therapy before CBT; second, the chemotherapy/radiotherapy used in the conditioning regimen; 2 third, the immunosuppression drugs used after CBT in the GVHD prophylaxis. 3 However, two of our cases (cases 2 and 3) received female cord blood cells and the transient chromosomal abnormalities were observed only in recipient cells, suggesting that the causing event occurred before the CBT. The induction of these chromosomal rearrangements by ALL treatment can be ruled out because two of our patients (cases 1 and 2) showed a normal karyotype before CBT. So, the transient abnormalities might have been caused by the conditioning regimen. Our patients received chemotherapy (Cytarabine and ATG) and fractionated TBI. The patient described by Kim et al. 1 received a similar conditioning regimen. Balanced chromosome rearrangements are well documented in therapy-related leukemia that develops in patients treated with topoisomerase II inhibitors. 4 However, there are no reports of cases with chromosomal abnormalities after therapy with Cytarabine or ATG. Moreover, Barrios et al. 5 have reported the cytogenetic effects of radiotherapy. These researchers observed that chromosomes 1, 3 and 7 were significantly more affected than other chromosomes by ionizing radiation in vivo. Chromosome regions 1p, 1q, 7q and 11p were also significantly more affected. Some chromosomal regions also showed a special sensitivity to radiation, and the q32 of chromosome 1 was the most affected. Our patients showed various translocations and other chromosomal rearrangements in these regions cited by Barrios et al. 5 Basically, all the chromosomal regions were involved. However, in our study the most frequent chromosomal regions involved in rearrangements were 7q, 6q and 11p. Interesting was the large number of rearrangements involving the 6q region, which lead us to believe that this region is also sensitive to radiation. Rearrangements in 6q might be associated with malignant transformation, as 6q21 has been described as a possible recessive tumor suppressor gene. 6 In relation to secondary leukemia and MDS, the 7q region always has the strongest association. Alterations involving 7q have been frequently described in secondary MDS. 7 The significance of transient rearrangements after SCT is still not clear. Some reports correlated transient chromosomal rearrangement with relapse or secondary disease, such as myelodysplastic syndrome, 8 but other studies observed no clinical evidence after CBT. 2 In our cases, the transient chromosomal rearrangements were associated with delayed hematological recovery, primary rejection and autologous reconstitution without disease evidence or secondary malignancy. The patient described by Kim et al.
1 also presented autologous reconstitution. Extensive research over the last 20 years has established the safety and efficacy of CBT in both children and adults, this being the strategy widely used to treat children affected by many disorders. In comparison to BMT, the advantages of CBT are represented by lower incidence and severity of GVHD, easier procurement and 9 Owing to these advantages, the number of CBT will increase in coming years. Although the long-term consequences of transient chromosomal rearrangements are not clear, the possibility of less aggressive conditioning regimens, especially for children, should be considered. Some authors are already suggesting the development of non-high-dose TBI-based conditioning regimens as an area of active investigation, with the goals of retaining potent anti-malignancy potential and reducing the toxicity of high-dose TBI while establishing regimens that remain sufficiently immunosuppressive to ensure engraftment. 10 More cases and a longer follow-up are needed to elucidate the real clinical significance of the transient chromosomal rearrangements in patients treated with CBT.
